Does Earnings Surprise History Hold Any Clue for NASDAQ:MNPR, NASDAQ:CETX, NASDAQ:FMTX, NASDAQ:DUO

MONOPAR THERAPEUTICS (NASDAQ:MNPR) EARNINGS INFORMATION (NASDAQ:MNPR)

Monopar Therapeutics last announced its earnings data on August 12th, 2021. The reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.02. Monopar Therapeutics has generated ($0.58) earnings per share over the last year (($0.76) diluted earnings per share). Earnings for Monopar Therapeutics are expected to decrease in the coming year, from ($0.86) to ($1.33) per share. Monopar Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 11th, 2021 based off prior year’s report dates.

IS MONOPAR THERAPEUTICS A BUY RIGHT NOW? (NASDAQ:MNPR)

3 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Monopar Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Monopar Therapeutics stock.
Monopar Therapeutics

CEMTREX (NASDAQ:CETX) EARNINGS INFORMATION (NASDAQ:CETX)

Cemtrex last released its quarterly earnings data on June 23rd, 2021. The industrial products company reported ($0.07) earnings per share (EPS) for the quarter. The firm earned $9.26 million during the quarter. Cemtrex has generated $0.00 earnings per share over the last year.

IS CEMTREX A BUY RIGHT NOW? (NASDAQ:CETX)

1 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Cemtrex in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should “buy” Cemtrex stock.
Cemtrex

FORMA THERAPEUTICS (NASDAQ:FMTX) EARNINGS INFORMATION (NASDAQ:FMTX)

Forma Therapeutics last issued its quarterly earnings data on May 13th, 2021. The reported ($0.76) EPS for the quarter, meeting analysts’ consensus estimates of ($0.76). Forma Therapeutics has generated ($3.22) earnings per share over the last year (($6.69) diluted earnings per share). Earnings for Forma Therapeutics are expected to decrease in the coming year, from ($3.10) to ($3.73) per share.

IS FORMA THERAPEUTICS A BUY RIGHT NOW? (NASDAQ:FMTX)

6 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Forma Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” Forma Therapeutics stock.
Forma Therapeutics

FANGDD NETWORK GROUP (NASDAQ:DUO) EARNINGS INFORMATION (NASDAQ:DUO)

Fangdd Network Group last released its earnings results on May 14th, 2021. The reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by $0.01. The business had revenue of $44.89 million for the quarter, compared to analysts’ expectations of $41.54 million. Fangdd Network Group has generated ($0.40) earnings per share over the last year (($0.35) diluted earnings per share).

WHAT STOCKS DOES MARKETBEAT LIKE BETTER THAN FANGDD NETWORK GROUP? (NASDAQ:DUO)

Wall Street analysts have given Fangdd Network Group a “N/A” rating, but there may be better buying opportunities in the stock market. Some of MarketBeat’s past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Fangdd Network Group wasn’t one of them. MarketBeat thinks these five companies may be even better buys.